PCA
AXSM icon

Pallas Capital Advisors’s Axsome Therapeutics AXSM Stock Holding History

Pallas Capital Advisors’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.92M Sell
40,511
-99
-0.2% -$21.5K 0.31% 59
2026
Q1 		$6.86M Sell
40,610
-3,299
-8% -$570K 0.26% 73
2025
Q4 		$8.02M Buy
43,909
+4,465
+11% +$623K 0.26% 72
2025
Q3 		$4.79M Buy
39,444
+1,672
+4% +$188K 0.18% 97
2025
Q2 		$3.94M Buy
37,772
+2,492
+7% +$264K 0.15% 111
2025
Q1 		$4.11M Buy
35,280
+8,845
+33% +$1.01M 0.17% 113
2024
Q4 		$2.24M Buy
+26,435
New +$2.43M 0.1% 149

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Pallas Capital Advisors's AXSM Position: Q2 2026 in Review

Pallas Capital Advisors reduced its Axsome Therapeutics (AXSM) stake by 0.24% in Q2 2026, selling an estimated $21.5K and leaving 40,511 shares worth $9.92M. The position accounts for 0.31% of the portfolio, ranked #59.

Pallas Capital Advisors first reported a position in AXSM in Q4 2024 and has held it in 7 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Pallas Capital Advisors held 40,511 shares of Axsome Therapeutics worth $9.92M as of Q2 2026.
  • Pallas Capital Advisors sold 99 Axsome Therapeutics shares in Q2 2026, an estimated $21.5K.
  • Axsome Therapeutics made up 0.31% of Pallas Capital Advisors's portfolio in Q2 2026, its #59 holding.
  • Pallas Capital Advisors first reported a position in Axsome Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Pallas Capital Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.